EL7.AI
StocksMediumUpdated•Originally published 23 March 2026•Updated 23 March 2026•
1 min read

Samsung Biologics Labor Dispute Threatens Global Biotech Supply Chains

Key Facts

1Samsung Biologics labor union, representing 75% of the workforce, warns of a potential strike.
2The union cites severe ESG and governance failures as the root cause of the dispute.
3The dispute threatens to create structural supply chain risks in the global CDMO (Contract Development and Manufacturing Organization) sector.

The labor union at Samsung Biologics has issued a formal warning regarding a potential strike, citing systemic governance failures. Representing approximately 75% of the company's workforce, the union's move poses a significant threat to operational stability and global manufacturing commitments. The dispute centers on allegations of severe lapses in ESG standards and corporate governance within the organization. Industry experts warn that a work stoppage could create structural risks across the global CDMO sector, where Samsung Biologics is a dominant player. This escalation follows a broader trend of labor unrest within the Samsung Group, now expanding to its critical biotechnology growth engine. Market sentiment remains cautious as the potential disruption could impact the company's stock performance and its standing with international partners.